文献速递关节外科骨质疏松与代谢性骨病创伤骨科

镰状细胞病患者全髋关节置换术:一项综合系统综述

Total Hip Arthroplasty in Patients With Sickle Cell Disease: A Comprehensive Systematic Review.
PubMed 文献 · J Arthroplasty · 2020-04-11

SCD患者术后Harris髋关节评分与Merle d'Aubigne评分显著提高,但住院时间、30天和90天再入院率、内科并发症(疼痛危象、急性胸部综合征、心脏并发症、脓毒症、死亡)及外科并发症(伤口并发症、感染、假体周围骨折、无菌性松动)均高于非SCD患者,翻修率也高于原发性骨关节炎患者。THA仍是SCD患者髋关节骨坏死的有效治疗,但围手术期风险需重视。

要点

  • SCD患者THA术后Harris髋关节评分与Merle d'Aubigne评分显著提高。
  • SCD患者住院时间、30天和90天再入院率、内科及外科并发症率均高于非SCD患者。
  • SCD患者THA翻修率高于原发性骨关节炎患者。

核心结论

  • THA仍是SCD患者髋关节骨坏死的有效治疗方式,但患者内科和外科并发症风险增加。

研究设计与样本

  • 遵循PRISMA指南系统检索PubMed、MEDLINE、EMBASE和Cochrane数据库。
  • Coleman证据质量评分范围为差至中等。

主要发现

  • SCD患者THA术后Harris髋关节评分和Merle d'Aubigne评分显著提高。
  • 与非SCD患者相比,SCD患者住院时间、30天和90天再入院率增加。
  • SCD患者内科并发症增加,包括疼痛危象、急性胸部综合征、心脏并发症、脓毒症和死亡。
  • SCD患者外科并发症增加,包括伤口并发症、感染、假体周围骨折和无菌性松动。
  • SCD患者THA翻修率高于原发性骨关节炎患者。

临床怎么用

  • 向SCD患者咨询和管理围手术期时,外科医生应知晓该人群的独特挑战。

局限性

  • 纳入研究的Coleman证据质量评分范围为差至中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total hip arthroplasty (THA) is a common treatment for end-stage osteonecrosis of the hip in patients with sickle cell disease (SCD). This patient population presents unique challenges in the perioperative period. This systematic review aims to investigate the existing literature on the outcomes, complications, and survivorship of primary THA in SCD patients. METHODS: A systematic search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed of PubMed, MEDLINE, EMBASE, and Cochrane databases for clinical studies on THA in SCD patients. Studies on primary THA in SCD patients with a mean follow-up greater than 90 days were included. RESULTS: Sixteen studies containing 5193 SCD patients met criteria for inclusion. The Coleman Quality of Evidence score ranged from poor to moderate. SCD patients had a significant increase in Harris Hip Scores and Merle d'Aubigne Scores after undergoing THA. Compared to non-SCD patients, SCD patients had increased hospital length-of-stay, 30-day and 90-day readmission rates, and rates of medical complications, including pain crises, acute chest syndrome, cardiac complications, sepsis, and mortality. SCD patients also had increased rates of surgical complications, including wound complications, infection, periprosthetic fracture, and aseptic loosening. Overall, THA revision rates were higher in SCD patients relative to those with primary osteoarthritis. CONCLUSION: THA remains an effective treatment modality for osteonecrosis of the hip in SCD patients. However, these patients are at increased risk of medical and surgical complications. Surgeons should be aware of the unique challenges in this patient population when counseling and managing these patients in the perioperative period.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Fassihi SC, Lee R, Quan T, et al. Total Hip Arthroplasty in Patients With Sickle Cell Disease: A Comprehensive Systematic Review. J Arthroplasty. 2020. PMID: 32376165. doi:10.1016/j.arth.2020.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。